Chemical compound
Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes.[1] It is no longer in phase III clinical trials.[2]
References
- ^ "Statement on a nonproprietary name adopted by the USAN Council: Aleglitazar" (PDF). United States Adopted Names. American Medical Association. Retrieved 2008-08-17.
- ^ "Roche halts diabetes drug trial in blow to pipeline". Roche. 2013-07-10. Retrieved 2013-07-10.
| PPARαTooltip Peroxisome proliferator-activated receptor alpha |
|
|---|---|
| PPARδTooltip Peroxisome proliferator-activated receptor delta | |
| PPARγTooltip Peroxisome proliferator-activated receptor gamma |
|
| Non-selective | |
| |